Funders and leaders of health and social services are increasingly seeking evidence-based solutions to help address demands brought about by demographic shifts, high prevalence of chronic diseases, and economic constraints affecting populations and systems of care. Reliable data on the efficacy and cost-effectiveness of therapies and treatment strategies derived from randomized clinical trials are assuming greater priority (and a peer-review preference) for funding bodies of clinical research rather than simply (further) describing the burden of a condition or situation. Yet, the latter research is central to our understanding of the patterns and risks of health conditions and in designing and testing intervention strategies. The article by Jørgensen et al1 is therefore an important reminder of the value of conventional “shoe leather” analytical epidemiology in providing a seminal appraisal of the well-recognized but poorly understood and treated disorder of stroke-associated depression.
Anderson CS. Depression After Stroke—Frequency, Risk Factors, and Mortality Outcomes. JAMA Psychiatry. 2016;73(10):1013-1014. doi:10.1001/jamapsychiatry.2016.1868